Mixed Dyslipidemia
📧 Sign up to get email alerts when something new happens for Mixed Dyslipidemia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2026-03-11FDA Approved: FENOFIBRIC ACID — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for Fenofibric acid by Alembic Pharmaceuticals Limited.
-
FDA approval · 2026-01-21FDA Approved: FENOFIBRATE — Original Application (Macleods Pharmaceuticals Limited)
FDA approved Macleods Pharmaceuticals Limited's fenofibrate under an Original Application (ANDA 210379). The approval permits the generic fe…
-
FDA approval · 2025-10-01FDA Approved: FENOFIBRATE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Fenofibrate submitted by Lupin Pharmaceuticals, Inc., indicating a regulatory change to this…
-
FDA approval · 2025-08-28FDA Approved: FENOFIBRATE — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA approved Camber Pharmaceuticals' supplemental application for fenofibrate, authorizing continued marketing of fenofibrate for lipid-…
-
FDA approval · 2025-08-21FDA Approved: FENOFIBRATE — Supplemental Application (AvKARE)
FDA approved a supplemental application for Fenofibrate by AvKARE. This approval supports the generic product's marketing under an approved …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-08-21FDA Approved: FENOFIBRATE — Supplemental Application (Cipla USA Inc.)
FDA approved a supplemental application for fenofibrate filed by Cipla USA Inc. under the ANDA 208709.
-
FDA approval · 2025-05-22FDA Approved: FENOFIBRATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries, Inc.'s supplemental application for fenofibrate (generic) under ANDA 201748, authorizing the mar…
-
FDA approval · 2024-11-13FDA Approved: FENOFIBRATE — Original Application (Macleods Pharmaceuticals Limited)
FDA approved Macleods Pharmaceuticals Limited's fenofibrate as an Original Application generic (ANDA 210248). This marks the approval of a g…
-
FDA approval · 2024-11-06FDA Approved: ROSUVASTATIN — Original Application (Macleods Pharmaceuticals Limited)
FDA approved the original application for rosuvastatin by Macleods Pharmaceuticals Limited, establishing a generic rosuvastatin product. Thi…
-
FDA approval · 2024-10-15FDA Approved: ROSUVASTATIN CALCIUM — Supplemental Application (Glenmark Pharmaceutials Inc., USA)
FDA approved a supplemental application for rosuvastatin calcium from Glenmark Pharmaceuticals, confirming regulatory approval of this gener…
-
FDA approval · 2024-07-10FDA Approved: EZETIMIBE — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' supplemental application for ezetimibe (ANDA 210859). This is a routine supplemental approval for a gen…
-
FDA approval · 2024-07-10FDA Approved: EZETIMIBE — Supplemental Application (Marlex Pharmaceuticals, Inc.)
The FDA approved a supplemental application for ezetimibe submitted by Marlex Pharmaceuticals, Inc., granting an update to the approved gene…
-
FDA approval · 2024-07-10FDA Approved: EZETIMIBE AND SIMVASTATIN — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for a generic Ezetimibe and Simvastatin combination from Aurobindo Pharma Limited.
-
FDA approval · 2024-04-30FDA Approved: PITAVASTATIN CALCIUM — Original Application (NorthStar RxLLC)
FDA approved NorthStar RxLLC's original application for pitavastatin calcium, a generic statin, to treat hyperlipidemia by lowering choleste…
-
FDA approval · 2024-03-29FDA Approved: EZETIMIBE — Supplemental Application (Quallent Pharmaceuticals Health LLC)
The FDA approved a supplemental application for ezetimibe filed by Quallent Pharmaceuticals Health LLC. This confirms approval of a new or m…
-
FDA approval · 2024-03-22FDA Approved: NEXLIZET — Supplemental Application (Esperion Therapeutics, Inc.)
The FDA approved a supplemental application for Nexlizet (bempedoic acid and ezetimibe) by Esperion Therapeutics.
-
FDA approval · 2024-02-21FDA Approved: ZETIA — Supplemental Application (Organon LLC)
FDA approved a supplemental application for Zetia (ezetimibe) from Organon LLC.
-
FDA approval · 2024-02-08FDA Approved: FENOFIBRIC ACID — Original Application (Macleods Pharmaceuticals Limited)
FDA approved an original application for fenofibric acid (generic) manufactured by Macleods Pharmaceuticals Limited.
-
FDA approval · 2024-01-31FDA Approved: FENOFIBRATE — Original Application (Chartwell RX, LLC.)
FDA approved fenofibrate (generic) under Original Application ANDA211407 for Chartwell RX, LLC. This marks the approval of a first generic v…
-
FDA approval · 2023-09-20FDA Approved: FENOFIBRIC ACID — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for fenofibric acid from Aurobindo Pharma Limited, updating the product’s labeling as part of the su…
-
FDA approval · 2023-08-09FDA Approved: ZOCOR — Supplemental Application (Organon LLC)
FDA approved a Supplemental Application for ZOCOR (simvastatin) submitted by Organon LLC.
-
FDA approval · 2023-03-27FDA Approved: FENOFIBRATE — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA approved Camber Pharmaceuticals' Fenofibrate supplemental application.
-
FDA approval · 2023-03-27FDA Approved: FENOFIBRATE — Supplemental Application (Westminster Pharmaceuticals, LLC)
The FDA approved a supplemental application for fenofibrate from Westminster Pharmaceuticals, LLC, authorizing changes to the generic produc…
-
FDA approval · 2023-01-03FDA Approved: ATORVASTATIN CALCIUM — Supplemental Application (Ascend Laboratories, LLC)
The FDA approved a supplemental application for atorvastatin calcium from Ascend Laboratories, LLC, approving the generic atorvastatin calci…
-
FDA approval · 2022-05-25FDA Approved: FENOFIBRATE — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved ANI Pharmaceuticals’ supplemental application for fenofibrate, authorizing the marketing of a generic fenofibrate product.